The BioNTech SE ADR BNTX slid 2.22% to $106.32 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 and Dow Jones ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

British prosecutors accuse Thomas Kwan of posing as a nurse and injecting 72-year-old Patrick O'Hara with a dangerous ...